AJOVista LLC Invests $221,000 in Gilead Sciences, Inc. (NASDAQ:GILD)

AJOVista LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 2,728 shares of the biopharmaceutical company’s stock, valued at approximately $221,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of GILD. OFI Invest Asset Management acquired a new stake in Gilead Sciences during the third quarter worth about $26,000. Tompkins Financial Corp increased its position in Gilead Sciences by 223.1% during the third quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares during the last quarter. Fortitude Family Office LLC acquired a new stake in Gilead Sciences during the fourth quarter worth about $29,000. Rakuten Securities Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $33,000. Finally, Financial Connections Group Inc. acquired a new stake in shares of Gilead Sciences during the fourth quarter valued at about $40,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on the company. Truist Financial cut Gilead Sciences from a “buy” rating to a “hold” rating and cut their price target for the company from $91.00 to $82.00 in a research note on Thursday, February 22nd. HSBC upgraded Gilead Sciences from a “reduce” rating to a “hold” rating and set a $69.00 target price on the stock in a research report on Wednesday, April 24th. UBS Group cut their target price on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 17th. TD Cowen cut their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a research report on Friday, April 26th. Finally, Royal Bank of Canada cut their target price on Gilead Sciences from $76.00 to $74.00 and set a “sector perform” rating on the stock in a research report on Friday, April 26th. Eleven investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $83.69.

Gilead Sciences Stock Performance

GILD traded down $0.55 during trading on Friday, reaching $64.78. The company’s stock had a trading volume of 7,822,720 shares, compared to its average volume of 7,345,331. Gilead Sciences, Inc. has a 52-week low of $64.33 and a 52-week high of $87.86. The company’s fifty day moving average price is $70.55 and its 200-day moving average price is $75.83. The company has a market capitalization of $80.66 billion, a price-to-earnings ratio of 179.94, a price-to-earnings-growth ratio of 1.30 and a beta of 0.22. The company has a debt-to-equity ratio of 1.08, a quick ratio of 0.72 and a current ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.49) by $0.17. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company had revenue of $6.69 billion for the quarter, compared to analyst estimates of $6.36 billion. During the same quarter in the previous year, the company earned $1.37 EPS. The firm’s revenue for the quarter was up 5.3% compared to the same quarter last year. On average, equities analysts forecast that Gilead Sciences, Inc. will post 3.74 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 27th. Stockholders of record on Friday, June 14th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 4.75%. The ex-dividend date is Friday, June 14th. Gilead Sciences’s dividend payout ratio (DPR) is 855.56%.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $72.96, for a total transaction of $145,920.00. Following the sale, the insider now owns 96,304 shares of the company’s stock, valued at approximately $7,026,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.